Quick Answer
Petros Pharmaceuticals, Inc. reported Gross Profit of $3.90 million for the year ending 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -7.0% in Gross Profit from 2023 to 2024.
- This data is from Petros Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $1.01 million | Q2 2020: $834.3 thousand | Q3 2020: $2.48 million | Q1 2021: $3.43 million | Q2 2021: $2.06 million | Q3 2021: $1.83 million | Q1 2022: $1.99 million | Q2 2022: $3.54 million | Q3 2022: -$1.74 million | Q1 2023: $1.97 million | Q2 2023: $1.48 million | Q3 2023: $1.27 million | Q1 2024: $1.06 million | Q2 2024: $1.09 million | Q3 2024: $1.29 million.
- Over the full 5 years of available data (2020 to 2024), Petros Pharmaceuticals, Inc.'s Gross Profit has declined by 29.3%.
- Historical annual values: Fiscal year 2024: $3.90 million | Fiscal year 2023: $4.19 million | Fiscal year 2022: $3.70 million | Fiscal year 2021: $6.21 million | Fiscal year 2020: $5.51 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: